Characteristics of study sample by transcobalamin II genotype
| . | Transcobalamin II genotype . | ||
|---|---|---|---|
| PP . | PR . | RR . | |
| N | 39 | 63 | 26 |
| Sex (men/women) | 33/6 | 54/9 | 21/5 |
| Age (y) | 66 (± 11) | 67 (± 11) | 67 (± 11) |
| B12 (pg/mL) | 433 (± 177) | 415 (± 168) | 383 (± 191) |
| HoloTCII (pg/mL) | 150 (± 81) | 113 (± 56)* | 104 (± 83)* |
| % Total B12 on TCII† | 34.3 (± 9.5) | 27.8 (± 9.9)* | 24.6 (± 10.1)* |
| Methylmalonic acid (nM) | 208 (± 96) | 206 (± 80) | 264 (± 138)‡ |
| Homocysteine (μM) | 10.3 (± 2.6) | 10.7 (± 2.4) | 11.2 (± 2.8) |
| RBC folate (ng/mL) | 363 (± 97) | 378 (± 106) | 398 (± 106) |
| Creatinine (mg/dL) | 1.1 (± 0.9) | 1.1 (± 1.0) | 1.1 (± 0.6) |
| Hematocrit (%) | 43.4 (± 3.2) | 43.8 (± 3.5) | 43.6 (± 3.3) |
| MCV (μm3) | 93.9 (± 3.2) | 92.9 (± 3.2) | 92.2 (± 5.1) |
| . | Transcobalamin II genotype . | ||
|---|---|---|---|
| PP . | PR . | RR . | |
| N | 39 | 63 | 26 |
| Sex (men/women) | 33/6 | 54/9 | 21/5 |
| Age (y) | 66 (± 11) | 67 (± 11) | 67 (± 11) |
| B12 (pg/mL) | 433 (± 177) | 415 (± 168) | 383 (± 191) |
| HoloTCII (pg/mL) | 150 (± 81) | 113 (± 56)* | 104 (± 83)* |
| % Total B12 on TCII† | 34.3 (± 9.5) | 27.8 (± 9.9)* | 24.6 (± 10.1)* |
| Methylmalonic acid (nM) | 208 (± 96) | 206 (± 80) | 264 (± 138)‡ |
| Homocysteine (μM) | 10.3 (± 2.6) | 10.7 (± 2.4) | 11.2 (± 2.8) |
| RBC folate (ng/mL) | 363 (± 97) | 378 (± 106) | 398 (± 106) |
| Creatinine (mg/dL) | 1.1 (± 0.9) | 1.1 (± 1.0) | 1.1 (± 0.6) |
| Hematocrit (%) | 43.4 (± 3.2) | 43.8 (± 3.5) | 43.6 (± 3.3) |
| MCV (μm3) | 93.9 (± 3.2) | 92.9 (± 3.2) | 92.2 (± 5.1) |
Values represent means (± SD).
Calculated using the equation: 100 × (holoTCII/total B12).
Significantly less than PP genotype after controlling for potential confounding by age, sex, and total B12 (P ≤ .006).
Significantly greater than PP and PR genotypes after controlling for potential confounding by age, sex, total B12, and creatinine (P ≤ .02).